CAREstream Group has entered into an exclusive licensing agreement with Cytonics Corporation, a biotechnology company focused on developing therapies for osteoarthritis (OA)
CAREstream America, a premier product and services distributor for pain management, regenerative and aesthetic specialties, has entered into an exclusive licensing agreement with Cytonics Corporation, a biotechnology company focused on developing therapies for Osteoarthritis (OA). Under the agreement terms, CAREstream America will acquire the global rights for the next 10 years to Cytonics’ patented Autologous Platelet Integrated Concentrate (APICTM) system, including subsequent autologous therapies specific in the treatment of pain, inflammation, the degeneration of joints and osteoarthritic pain for the human marketplace.
“Cytonics’ mission is to build world-class therapies to rid the world of debilitating musculoskeletal diseases. To this end, we are thrilled to partner with CAREstream America to market and distribute the APIC technology on a global scale, bringing affordable relief to patients around the world. The APIC system is a perfect complement to CAREstream’s regenerative medicine product line, and we are confident that the CAREstream team will bring visibility to our A2M-based technologies and provide support for our ongoing research and development programs,” added Cytonics Corporation President, Joey Bose.
Cytonics’ APICTM system concentrates and purifies the Alpha-2-Macroglobulin (A2M) molecule from patients’ blood, producing a therapeutic composition that is injected into damaged joints. This proprietary, and FDA approved technology, is changing the way physicians manage pain for their patients.
In June 2020, CAREstream America will re-launch this unique therapy solution in the USA under the brand ALPHA2ACTIVETM. Visit www.carestreamamerica.com for more details.
CAREstream America President, Blake Petrunick, commented on the new agreement saying, “We are proud to be the exclusive distributors for Alpha2ActiveTM around the world. We will focus our extensive sales efforts on the domestic market followed by an international introduction of this incredible therapy.”
Source: Company Press Release